Treatment Options for Inoperable and Metastatic Malignant Melanoma:@0.248549:0.035749:0.914584:0.035749:0.914584:0.019993:0.248549:0.019993:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.016722:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330:0.004349:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330:0.017684:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.017684:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330:0.017684:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
73:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Dr A Bonthuys:@0.084848:0.179499:0.213003:0.179499:0.213003:0.163465:0.084848:0.163465:0.013470:0.006158:0.005388:0.014239:0.005388:0.011161:0.012315:0.011545:0.005773:0.011545:0.011545:0.011161:0.008467
MBChB; MSc; F.C. Rad Onc (SA);  :@0.084848:0.195956:0.394978:0.195956:0.394978:0.179737:0.084848:0.179737:0.017318:0.011161:0.015009:0.011545:0.011161:0.005388:0.005388:0.017318:0.010006:0.012315:0.005388:0.005388:0.009236:0.005388:0.015009:0.005388:0.005388:0.011161:0.012700:0.012700:0.005388:0.016164:0.011545:0.012315:0.005388:0.007312:0.010006:0.014239:0.007312:0.005388:0.005330:0.005388
MMed (Rad Onc):@0.084848:0.212413:0.246485:0.212413:0.246485:0.196194:0.084848:0.196194:0.017318:0.017318:0.012315:0.012700:0.005388:0.007312:0.011161:0.012700:0.012700:0.005388:0.016164:0.011545:0.012315:0.007312
 :@0.084848:0.228751:0.121236:0.228751:0.121236:0.214067:0.084848:0.214067:0.017145:0.019242
ICON Clinical Executive:@0.121236:0.228870:0.340965:0.228870:0.340965:0.213114:0.121236:0.213114:0.004349:0.015644:0.016722:0.014239:0.005330:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.010314:0.009236:0.012508:0.012450:0.011699:0.006523:0.003848:0.010660:0.012508
Malignant melanoma accounts for less :@0.084848:0.261771:0.481088:0.261771:0.481088:0.246015:0.084848:0.246015:0.017684:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.012354:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.012354:0.013143:0.012450:0.012450:0.012604:0.011699:0.011738:0.006523:0.007466:0.012354:0.006042:0.012604:0.005792:0.012354:0.003848:0.012508:0.007466:0.007466:0.005330
than 5% of all  cutaneous  malignancies, :@0.084848:0.278228:0.481090:0.278228:0.481090:0.262472:0.084848:0.262472:0.006523:0.011738:0.013143:0.011738:0.010564:0.010660:0.014913:0.010564:0.012604:0.006042:0.010564:0.013143:0.003848:0.003848:0.005330:0.005245:0.012450:0.011699:0.006523:0.013143:0.011738:0.012508:0.012604:0.011699:0.007466:0.005330:0.005224:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.003848:0.012508:0.007466:0.005330:0.005330
yet it is responsible for the majority of skin-:@0.084848:0.294685:0.475746:0.294685:0.475746:0.278929:0.084848:0.278929:0.010314:0.012508:0.006523:0.006100:0.003848:0.006523:0.006100:0.003848:0.007466:0.006100:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.013123:0.003848:0.012508:0.006100:0.006042:0.012604:0.005792:0.006090:0.006523:0.011738:0.012508:0.006100:0.018049:0.013143:0.003906:0.012604:0.005792:0.003848:0.006523:0.010314:0.006100:0.012604:0.006042:0.006100:0.007466:0.009660:0.003848:0.011738:0.006388
cancer  deaths. The  incidence of  mela-:@0.084848:0.311142:0.475762:0.311142:0.475762:0.295387:0.084848:0.295387:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.005396:0.013181:0.012508:0.013143:0.006523:0.011738:0.007466:0.005330:0.010737:0.008197:0.011738:0.012508:0.005330:0.005394:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.010737:0.012604:0.006042:0.005330:0.005397:0.018049:0.012508:0.003848:0.013143:0.006388
noma  has been  steadily increasing  over :@0.084848:0.327600:0.481098:0.327600:0.481098:0.311844:0.084848:0.311844:0.011738:0.012604:0.018049:0.013143:0.005330:0.003735:0.011738:0.013143:0.007466:0.009082:0.013123:0.012508:0.012508:0.011738:0.005330:0.003735:0.007466:0.006523:0.012508:0.013143:0.013181:0.003848:0.003848:0.010314:0.009082:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.003848:0.011738:0.012950:0.005330:0.003741:0.012604:0.010660:0.012508:0.005792:0.005330
the past few decades and is currently the :@0.084848:0.344057:0.481099:0.344057:0.481099:0.328301:0.084848:0.328301:0.006523:0.011738:0.012508:0.005734:0.013123:0.013143:0.007466:0.006523:0.005738:0.006042:0.012508:0.015990:0.005740:0.013181:0.012508:0.012450:0.013143:0.013181:0.012508:0.007466:0.005753:0.013143:0.011738:0.013181:0.005740:0.003848:0.007466:0.005753:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.003848:0.010314:0.005740:0.006523:0.011738:0.012508:0.005330
fifth  most  common  cancer  in  men  and :@0.084848:0.360514:0.481094:0.360514:0.481094:0.344758:0.084848:0.344758:0.004686:0.004686:0.006042:0.006523:0.011738:0.005330:0.005178:0.018049:0.012604:0.007466:0.006523:0.005330:0.005190:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.005180:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.005180:0.003848:0.011738:0.005330:0.005190:0.018049:0.012508:0.011738:0.005330:0.005184:0.013143:0.011738:0.013181:0.005330
the sixth most common cancer in women :@0.084848:0.376971:0.481109:0.376971:0.481109:0.361215:0.084848:0.361215:0.006523:0.011738:0.012508:0.006106:0.007466:0.003848:0.009236:0.006523:0.011738:0.006119:0.018049:0.012604:0.007466:0.006523:0.006108:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.006102:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.006106:0.003848:0.011738:0.006119:0.015990:0.012604:0.018049:0.012508:0.011738:0.005330
worldwide, accounting for 6% and 4% of :@0.084848:0.393428:0.481086:0.393428:0.481086:0.377672:0.084848:0.377672:0.015990:0.012604:0.005792:0.003848:0.013181:0.015990:0.003848:0.013181:0.012508:0.005330:0.007870:0.013143:0.012450:0.012450:0.012604:0.011699:0.011738:0.006523:0.003848:0.011738:0.012950:0.007859:0.006042:0.012604:0.005792:0.007861:0.010660:0.014913:0.007870:0.013143:0.011738:0.013181:0.007870:0.010660:0.014913:0.007870:0.012604:0.006042:0.005330
new cancer cases respectively. The aver-:@0.084848:0.409885:0.475756:0.409813:0.475756:0.394057:0.084848:0.394129:0.011738:0.012508:0.015990:0.005586:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005580:0.012450:0.013143:0.007466:0.012508:0.007466:0.005600:0.005713:0.012508:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330:0.009481:0.008197:0.011738:0.012508:0.005580:0.013143:0.010660:0.012508:0.005792:0.412003
1 :@0.379767:0.404193:0.389089:0.404193:0.389089:0.395008:0.379767:0.395008:0.006215:0.003107
age age at diagnosis is 57 years, with the :@0.084847:0.426270:0.481067:0.426270:0.481067:0.410514:0.084847:0.410514:0.013143:0.012950:0.012508:0.006465:0.013143:0.012950:0.012508:0.006465:0.013143:0.006523:0.006465:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.006465:0.003848:0.007466:0.006465:0.010660:0.010660:0.006465:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.006465:0.015990:0.003848:0.006523:0.011738:0.006465:0.006523:0.011738:0.012508:0.005330
highest incidence occurring  between 55 :@0.084847:0.442727:0.481075:0.442727:0.481075:0.426971:0.084847:0.426971:0.011738:0.003848:0.012950:0.011738:0.012508:0.007466:0.006523:0.008582:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.008582:0.012604:0.012450:0.012450:0.011699:0.005792:0.005792:0.003848:0.011738:0.012950:0.005330:0.003240:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.008582:0.010660:0.010660:0.005330
and 74 years of age.  In addition, melano-:@0.084847:0.459184:0.475759:0.459166:0.475759:0.443410:0.084847:0.443428:0.013143:0.011738:0.013181:0.005109:0.010660:0.010660:0.005118:0.010314:0.012508:0.013143:0.005792:0.007466:0.005118:0.012604:0.006042:0.005103:0.013143:0.012950:0.012508:0.005330:0.006200:0.005107:0.004349:0.011738:0.005107:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.005107:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.340215
2:@0.276459:0.453546:0.282674:0.453546:0.282674:0.444361:0.276459:0.444361:0.006215
ma is the second most common cancer in :@0.084846:0.475623:0.481104:0.475623:0.481104:0.459867:0.084846:0.459867:0.018049:0.013143:0.004849:0.003848:0.007466:0.004849:0.006523:0.011738:0.012508:0.004849:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.004839:0.018049:0.012604:0.007466:0.006523:0.004849:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.004832:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004838:0.003848:0.011738:0.005330
young adults (age 15 to 29 years).:@0.084846:0.492080:0.401114:0.492080:0.401114:0.476324:0.084846:0.476324:0.010314:0.012604:0.011699:0.011738:0.012950:0.005330:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.005330:0.007100:0.013143:0.012950:0.012508:0.005330:0.010660:0.010660:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.005330:0.010314:0.012508:0.013143:0.005792:0.007466:0.007100:0.005330
3:@0.401108:0.486448:0.407323:0.486448:0.407323:0.477263:0.401108:0.477263:0.006215
The  vast majority of melanomas (84%) :@0.103030:0.508518:0.481076:0.508518:0.481076:0.492762:0.103030:0.492762:0.008197:0.011738:0.012508:0.005330:0.004397:0.010660:0.013143:0.007466:0.006523:0.009737:0.018049:0.013143:0.003906:0.012604:0.005792:0.003848:0.006523:0.010314:0.009737:0.012604:0.006042:0.009737:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.007466:0.009737:0.007100:0.010660:0.010660:0.014913:0.007100:0.005330
present at an early stage and may be cu-:@0.084846:0.524975:0.475773:0.524975:0.475773:0.509220:0.084846:0.509220:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005351:0.013143:0.006523:0.005357:0.013143:0.011738:0.005355:0.012508:0.013143:0.005792:0.003848:0.010314:0.005369:0.007466:0.006523:0.013143:0.012950:0.012508:0.005355:0.013143:0.011738:0.013181:0.005357:0.018049:0.013143:0.010314:0.005369:0.013123:0.012508:0.005357:0.012450:0.011699:0.006388
ratively managed with surgical resection. :@0.084846:0.541433:0.481080:0.541433:0.481080:0.525677:0.084846:0.525677:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.007389:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.013181:0.007389:0.015990:0.003848:0.006523:0.011738:0.007389:0.007466:0.011699:0.005807:0.012950:0.003848:0.012450:0.013143:0.003848:0.007389:0.005713:0.012508:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
This  provides  excellent  five-year  overall :@0.084846:0.557890:0.481088:0.557890:0.481088:0.542134:0.084846:0.542134:0.008197:0.011738:0.003848:0.007466:0.005330:0.007745:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.012508:0.007466:0.005330:0.007753:0.012508:0.009236:0.012450:0.012508:0.003848:0.003848:0.012508:0.011738:0.006523:0.005330:0.007741:0.004686:0.004686:0.010660:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.005330:0.007743:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330
survival rates which approach 98%. Loco-:@0.084846:0.574347:0.475761:0.574347:0.475761:0.558591:0.084846:0.558591:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006619:0.005792:0.013143:0.006523:0.012508:0.007466:0.006608:0.015990:0.011738:0.003848:0.012450:0.011738:0.006608:0.013143:0.013123:0.013123:0.005721:0.012604:0.013143:0.012450:0.011738:0.006604:0.010660:0.010660:0.014913:0.005330:0.006619:0.008890:0.012604:0.012450:0.012604:0.006388
regional nodal metastases are found in 9% :@0.084846:0.590804:0.481092:0.590804:0.481092:0.575048:0.084846:0.575048:0.005713:0.012508:0.012950:0.003848:0.012604:0.011738:0.013143:0.003848:0.004580:0.011738:0.012604:0.013181:0.013143:0.003848:0.004580:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.004580:0.013143:0.005715:0.012508:0.004580:0.006042:0.012604:0.011699:0.011738:0.013181:0.004568:0.003848:0.011738:0.004580:0.010660:0.014913:0.005330
of patients at diagnosis, and here the five-:@0.084846:0.607261:0.475754:0.607261:0.475754:0.591505:0.084846:0.591505:0.012604:0.006042:0.005130:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005134:0.013143:0.006523:0.005134:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.005140:0.013143:0.011738:0.013181:0.005134:0.011738:0.012508:0.005707:0.012508:0.005134:0.006523:0.011738:0.012508:0.005126:0.004686:0.004686:0.010660:0.012508:0.006388
year overall survival rates are around 63%. :@0.084846:0.623718:0.481086:0.623718:0.481086:0.607962:0.084846:0.607962:0.010314:0.012508:0.013143:0.005792:0.005530:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005542:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005542:0.005792:0.013143:0.006523:0.012508:0.007466:0.005526:0.013143:0.005715:0.012508:0.005530:0.013143:0.005713:0.012604:0.011699:0.011738:0.013181:0.005524:0.010660:0.010660:0.014913:0.005330:0.005330
Four percent of patients will have inopera-:@0.084846:0.640175:0.475752:0.640175:0.475752:0.624419:0.084846:0.624419:0.009333:0.012604:0.011699:0.005792:0.004778:0.013123:0.012508:0.005657:0.012450:0.012508:0.011738:0.006523:0.004782:0.012604:0.006042:0.004791:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004791:0.015990:0.003848:0.003848:0.003848:0.004791:0.011738:0.013143:0.010660:0.012508:0.004791:0.003848:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.006388
ble or metastatic disease at diagnosis. For :@0.084846:0.656632:0.481113:0.656632:0.481113:0.640876:0.084846:0.640876:0.013123:0.003848:0.012508:0.005638:0.012604:0.005792:0.005619:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005638:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005638:0.013143:0.006523:0.005626:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.005638:0.009333:0.012604:0.005792:0.005330
these patients, and for those who develop :@0.084846:0.673089:0.481080:0.673089:0.481080:0.657333:0.084846:0.657333:0.006523:0.011738:0.012508:0.007466:0.012508:0.004643:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004645:0.013143:0.011738:0.013181:0.004647:0.006042:0.012604:0.005792:0.004639:0.006523:0.011738:0.012604:0.007466:0.012508:0.004641:0.015990:0.011738:0.012604:0.004641:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.005330
recurrent or metastatic disease following :@0.084846:0.689546:0.481072:0.689546:0.481072:0.673790:0.084846:0.673790:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.006523:0.008524:0.012604:0.005792:0.008524:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.008524:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.008524:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
initial definitive therapy, treatment options :@0.084846:0.706003:0.481095:0.706003:0.481095:0.690247:0.084846:0.690247:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005095:0.013181:0.012508:0.004686:0.004686:0.011738:0.003848:0.006523:0.003848:0.010660:0.012508:0.005084:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005078:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005078:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
are limited, and five-year survival rates are :@0.084846:0.722460:0.481074:0.722460:0.481074:0.706705:0.084846:0.706705:0.013143:0.005715:0.012508:0.004955:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330:0.004953:0.013143:0.011738:0.013181:0.004957:0.004686:0.004686:0.010660:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.004953:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004966:0.005792:0.013143:0.006523:0.012508:0.007466:0.004953:0.013143:0.005715:0.012508:0.005330
less than 20%.:@0.084846:0.738918:0.211500:0.738918:0.211500:0.723162:0.084846:0.723162:0.003848:0.012508:0.007466:0.007466:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330:0.010660:0.010660:0.014913:0.005330
2:@0.211502:0.733213:0.217717:0.733213:0.217717:0.724027:0.211502:0.724027:0.006215
Treatment for metastatic disease  com-:@0.103030:0.755283:0.475769:0.755283:0.475769:0.739527:0.103030:0.739527:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.008544:0.006042:0.012604:0.005792:0.008544:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.008544:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.003229:0.012450:0.012604:0.018049:0.006388
prises systemic therapy with or without ra-:@0.084846:0.771740:0.475763:0.771740:0.475763:0.755984:0.084846:0.755984:0.013123:0.005792:0.003848:0.007466:0.012508:0.007466:0.006369:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.006369:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006369:0.015990:0.003848:0.006523:0.011738:0.006369:0.012604:0.005792:0.006369:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.006358:0.005792:0.013143:0.006388
diotherapy. Highly selective patients may :@0.084846:0.788197:0.481067:0.788197:0.481067:0.772441:0.084846:0.772441:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.007062:0.013143:0.003848:0.012950:0.011738:0.003848:0.010314:0.007062:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007062:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007062:0.018049:0.013143:0.010314:0.005330
be suitable for metastatectomy. Tradition-:@0.084846:0.804654:0.475759:0.804654:0.475759:0.788898:0.084846:0.788898:0.013123:0.012508:0.005588:0.007466:0.011699:0.003848:0.006523:0.013143:0.013123:0.003848:0.012508:0.005600:0.006042:0.012604:0.005792:0.005580:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.012508:0.012450:0.006523:0.012604:0.018038:0.010314:0.005330:0.005586:0.007622:0.005792:0.013143:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.006388
al approaches utilising cytotoxic chemo-:@0.084846:0.821111:0.475756:0.821111:0.475756:0.805355:0.084846:0.805355:0.013143:0.003848:0.008217:0.013143:0.013123:0.013123:0.005717:0.012604:0.013143:0.012450:0.011738:0.012508:0.007466:0.008217:0.011699:0.006523:0.003848:0.003848:0.003848:0.007466:0.003848:0.011738:0.012950:0.008217:0.012450:0.010314:0.006523:0.012604:0.006523:0.012592:0.009236:0.003848:0.012450:0.008217:0.012450:0.011738:0.012508:0.018049:0.012594:0.006388
therapy have shown disappointing results. :@0.084846:0.837568:0.481076:0.837568:0.481076:0.821812:0.084846:0.821812:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005619:0.011738:0.013143:0.010660:0.012508:0.005619:0.007466:0.011738:0.012604:0.015990:0.011738:0.005619:0.013181:0.003848:0.007466:0.013143:0.013123:0.013123:0.012615:0.003848:0.011738:0.006523:0.003848:0.011738:0.012950:0.005619:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330:0.005330
Chemotherapy has not been shown to im-:@0.084846:0.854025:0.475752:0.854025:0.475752:0.838269:0.084846:0.838269:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004524:0.011738:0.013143:0.007466:0.004541:0.011738:0.012604:0.006523:0.004528:0.013123:0.012508:0.012508:0.011738:0.004532:0.007466:0.011738:0.012604:0.015990:0.011738:0.004532:0.006523:0.012604:0.004530:0.003848:0.018049:0.006388
prove overall survival and response rates :@0.084846:0.870482:0.481074:0.870482:0.481074:0.854727:0.084846:0.854727:0.013123:0.005715:0.012604:0.010660:0.012508:0.008024:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.008036:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008041:0.013143:0.011738:0.013181:0.008024:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.008024:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330
are typically less than 20%. Those that do :@0.084846:0.886940:0.481090:0.886940:0.481090:0.871184:0.084846:0.871184:0.013143:0.005715:0.012508:0.007127:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.007139:0.003848:0.012508:0.007466:0.007466:0.007139:0.006523:0.011738:0.013143:0.011738:0.007124:0.010660:0.010660:0.014913:0.005330:0.007139:0.008197:0.011738:0.012604:0.007466:0.012508:0.007127:0.006523:0.011738:0.013143:0.006523:0.007124:0.013181:0.012604:0.005330
respond, have a median duration of re-:@0.084846:0.903397:0.475752:0.903397:0.475752:0.887641:0.084846:0.887641:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.005330:0.008967:0.011738:0.013143:0.010660:0.012508:0.008967:0.013143:0.008967:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.008967:0.013181:0.011699:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.008967:0.012604:0.006042:0.008967:0.005713:0.012508:0.006388
sponse of less than six months.  In an at-:@0.084846:0.919854:0.475772:0.919793:0.475772:0.904037:0.084846:0.904098:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.008217:0.012604:0.006042:0.008217:0.003848:0.012508:0.007466:0.007466:0.008217:0.006523:0.011738:0.013143:0.011738:0.008207:0.007466:0.003848:0.009236:0.008217:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.006202:0.008217:0.004349:0.011738:0.008217:0.013143:0.011738:0.008217:0.013143:0.006523:-0.329800
3:@0.377884:0.914174:0.384099:0.914174:0.384099:0.904988:0.377884:0.904988:0.006215
tempt to improve outcomes, recent years :@0.084843:0.936250:0.481092:0.936250:0.481092:0.920494:0.084843:0.920494:0.006523:0.012508:0.018049:0.013123:0.006523:0.005734:0.006523:0.012604:0.005734:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.005734:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.007466:0.005330:0.005723:0.005713:0.012508:0.012450:0.012508:0.011738:0.006523:0.005734:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330
have seen the emergence of several nov-:@0.524243:0.179502:0.915157:0.179502:0.915157:0.163746:0.524243:0.163746:0.011738:0.013143:0.010660:0.012508:0.005157:0.007466:0.012508:0.012508:0.011738:0.005147:0.006523:0.011738:0.012508:0.005145:0.012508:0.018049:0.012508:0.005804:0.012950:0.012508:0.011738:0.012450:0.012508:0.005142:0.012604:0.006042:0.005147:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.005157:0.011738:0.012604:0.010660:0.006388
el treatment options. In melanoma, these :@0.524243:0.195734:0.920498:0.195734:0.920498:0.179978:0.524243:0.179978:0.012508:0.003848:0.006581:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006567:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006569:0.004349:0.011738:0.006581:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.006569:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330
largely comprise immunotherapies and :@0.524243:0.211966:0.920493:0.211966:0.920493:0.196210:0.524243:0.196210:0.003848:0.013143:0.005813:0.012950:0.012508:0.003848:0.010314:0.013989:0.012450:0.012604:0.018049:0.013123:0.005792:0.003848:0.007466:0.012508:0.013989:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012496:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.013989:0.013143:0.011738:0.013181:0.005330
targeted therapies. Immunotherapy aims :@0.524243:0.228198:0.920477:0.228198:0.920477:0.212442:0.524243:0.212442:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.007889:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.003848:0.012508:0.007466:0.005330:0.007889:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006514:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007889:0.013143:0.003848:0.018049:0.007466:0.005330
to destroy malignant cells by inducing or :@0.524243:0.244431:0.920481:0.244431:0.920481:0.228675:0.524243:0.228675:0.006523:0.012604:0.007508:0.013181:0.012508:0.007466:0.006523:0.005713:0.012604:0.010314:0.007514:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.007510:0.012450:0.012508:0.003848:0.003848:0.007466:0.007524:0.013123:0.010314:0.007514:0.003848:0.011738:0.013181:0.011699:0.012450:0.003848:0.011738:0.012950:0.007514:0.012604:0.005792:0.005330
enhancing immune-system activation.:@0.524243:0.260663:0.881171:0.260663:0.881171:0.244907:0.524243:0.244907:0.012508:0.011738:0.011738:0.013143:0.011738:0.012450:0.003848:0.011738:0.012950:0.005330:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.005330:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
Immunotherapies fall into three general :@0.524243:0.293114:0.920500:0.293114:0.920500:0.277358:0.524243:0.277358:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.011180:0.006042:0.013143:0.003848:0.003848:0.011180:0.003848:0.011738:0.006523:0.012604:0.011180:0.006523:0.011738:0.005713:0.012508:0.012508:0.011180:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.005330
categories::@0.524243:0.309346:0.629365:0.309346:0.629365:0.293590:0.524243:0.293590:0.012450:0.013143:0.006523:0.012508:0.012950:0.012604:0.005792:0.003848:0.012508:0.007466:0.005330
n   :@0.524242:0.322425:0.547050:0.322425:0.547050:0.313985:0.524242:0.313985:0.009762:0.003566:0.005914:0.003566
Checkpoint inhibitors:@0.543484:0.325545:0.739179:0.325545:0.739179:0.309789:0.543484:0.309789:0.015644:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466
n   :@0.524242:0.338653:0.547050:0.338653:0.547050:0.330213:0.524242:0.330213:0.009762:0.003566:0.005914:0.003566
Cytokines and:@0.543484:0.341772:0.677180:0.341772:0.677180:0.326016:0.543484:0.326016:0.015644:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.007466:0.005330:0.013143:0.011738:0.013181
n   :@0.524242:0.354880:0.547050:0.354880:0.547050:0.346440:0.524242:0.346440:0.009762:0.003566:0.005914:0.003566
Anti-cancer vaccines.:@0.543484:0.357999:0.749224:0.357999:0.749224:0.342243:0.543484:0.342243:0.014239:0.011738:0.006523:0.003848:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.010660:0.013143:0.012450:0.012450:0.003848:0.011738:0.012508:0.007466:0.005330
Targeted therapies act on specific cellular :@0.524242:0.390450:0.920472:0.390450:0.920472:0.374694:0.524242:0.374694:0.007197:0.013143:0.005809:0.012950:0.012508:0.006523:0.012508:0.013181:0.005120:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.003848:0.012508:0.007466:0.005136:0.013143:0.012450:0.006523:0.005128:0.012604:0.011738:0.005120:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005128:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005330
pathways, targets  or  ligands and mostly :@0.524242:0.406682:0.920489:0.406682:0.920489:0.390927:0.524242:0.390927:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.007466:0.005330:0.009563:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.007466:0.005330:0.004224:0.012604:0.005792:0.005330:0.004218:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.009563:0.013143:0.011738:0.013181:0.009563:0.018049:0.012604:0.007466:0.006523:0.003848:0.010314:0.005330
result in inhibition of  cellular proliferation :@0.524242:0.422915:0.920506:0.422915:0.920506:0.407159:0.524242:0.407159:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.009525:0.003848:0.011738:0.009525:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.009525:0.012604:0.006042:0.005330:0.004183:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.009525:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
and tumour growth. The choice, sequenc-:@0.524242:0.439147:0.915153:0.439147:0.915153:0.423391:0.524242:0.423391:0.013143:0.011738:0.013181:0.004888:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004872:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330:0.004874:0.008197:0.011738:0.012508:0.004878:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.005330:0.004876:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.012450:0.006388
ing and combination of these approach-:@0.524242:0.455379:0.915165:0.455379:0.915165:0.439623:0.524242:0.439623:0.003848:0.011738:0.012950:0.006773:0.013143:0.011738:0.013181:0.006773:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006764:0.012604:0.006042:0.006764:0.006523:0.011738:0.012508:0.007466:0.012508:0.006764:0.013143:0.013123:0.013123:0.005719:0.012604:0.013143:0.012450:0.011738:0.006388
es remains essentially undefined and pa-:@0.524242:0.471611:0.915144:0.471611:0.915144:0.455855:0.524242:0.455855:0.012508:0.007466:0.007724:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.007728:0.012508:0.007466:0.007466:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.003848:0.010314:0.007734:0.011699:0.011738:0.013181:0.012508:0.004686:0.004686:0.011738:0.012508:0.013181:0.007709:0.013143:0.011738:0.013181:0.007722:0.013123:0.013143:0.006388
tients should be encouraged to enrol in :@0.524242:0.487843:0.920478:0.487843:0.920478:0.472087:0.524242:0.472087:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009410:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.009410:0.013123:0.012508:0.009410:0.012508:0.011738:0.012450:0.012604:0.011699:0.005792:0.013143:0.012950:0.012508:0.013164:0.009410:0.006523:0.012604:0.009410:0.012508:0.011738:0.005709:0.012604:0.003848:0.009410:0.003848:0.011738:0.005330
clinical trials whenever  possible. At  pre-:@0.524242:0.504076:0.915140:0.504076:0.915140:0.488320:0.524242:0.488320:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.010776:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.010776:0.015990:0.011738:0.012508:0.011738:0.012508:0.010660:0.012508:0.005792:0.005330:0.005428:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.010776:0.014239:0.006523:0.005330:0.005432:0.013123:0.005715:0.012508:0.006388
sent, treatment is largely directed by pa-:@0.524242:0.520308:0.915161:0.520308:0.915161:0.504552:0.524242:0.504552:0.007466:0.012508:0.011738:0.006523:0.005330:0.007389:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007387:0.003848:0.007466:0.007408:0.003848:0.013143:0.005811:0.012950:0.012508:0.003848:0.010314:0.007399:0.013181:0.003848:0.005717:0.012508:0.012450:0.006523:0.012508:0.013181:0.007393:0.013123:0.010314:0.007408:0.013123:0.013143:0.006388
tient-specific factors, drug availability and :@0.524242:0.536540:0.920470:0.536540:0.920470:0.520784:0.524242:0.520784:0.006523:0.003848:0.012508:0.011738:0.006523:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005455:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.005448:0.013181:0.005792:0.011699:0.012950:0.005448:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005478:0.013143:0.011738:0.013181:0.005330
affordability. This is a rapidly  expanding :@0.524242:0.552772:0.920497:0.552772:0.920497:0.537016:0.524242:0.537016:0.013143:0.006100:0.006042:0.012604:0.005671:0.013181:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.010757:0.008197:0.011738:0.003848:0.007466:0.010757:0.003848:0.007466:0.010757:0.013143:0.010757:0.005792:0.013143:0.013123:0.003848:0.013181:0.003848:0.010325:0.005330:0.005417:0.012508:0.009236:0.013123:0.013143:0.011738:0.013181:0.003848:0.011738:0.012950:0.005330
field of oncology and this ever-changing :@0.524242:0.569004:0.920493:0.569004:0.920493:0.553248:0.524242:0.553248:0.004686:0.004686:0.012508:0.003848:0.013181:0.007643:0.012604:0.006042:0.007641:0.012604:0.011738:0.012450:0.012604:0.003848:0.012590:0.012950:0.010314:0.007645:0.013143:0.011738:0.013181:0.007645:0.006523:0.011738:0.003848:0.007466:0.007647:0.012508:0.010660:0.012508:0.005792:0.006388:0.012450:0.011738:0.013143:0.011738:0.012950:0.003848:0.011738:0.012950:0.005330
landscape is a daunting one. An overview :@0.524242:0.585237:0.920487:0.585237:0.920487:0.569481:0.524242:0.569481:0.003848:0.013143:0.011738:0.013181:0.007466:0.012450:0.013143:0.013123:0.012508:0.004728:0.003848:0.007466:0.004726:0.013143:0.004714:0.013181:0.013143:0.011699:0.011738:0.006523:0.003848:0.011738:0.012950:0.004714:0.012604:0.011738:0.012508:0.005330:0.004714:0.014239:0.011738:0.004714:0.012604:0.010660:0.012508:0.005792:0.010660:0.003848:0.012508:0.015990:0.005330
of currently available systemic options will :@0.524242:0.601469:0.920458:0.601469:0.920458:0.585713:0.524242:0.585713:0.012604:0.006042:0.006061:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.003848:0.010314:0.006061:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.006086:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.006061:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.006061:0.015990:0.003848:0.003848:0.003848:0.005330
be briefly discussed.:@0.524242:0.617701:0.710046:0.617701:0.710046:0.601945:0.524242:0.601945:0.013123:0.012508:0.005330:0.013123:0.005792:0.003848:0.012508:0.004666:0.004666:0.010314:0.005330:0.013181:0.003848:0.007466:0.012450:0.011699:0.007466:0.007466:0.012508:0.013181:0.005330
TREATMENT OPTIONS FOR LOCALLY :@0.524242:0.650737:0.918882:0.650737:0.918882:0.631140:0.524242:0.631140:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878:0.006585:0.019756:0.013170:0.009878:0.006585:0.019756:0.017404:0.012230:0.006585:0.011289:0.019756:0.013641:0.006585:0.010348:0.019756:0.018344:0.017404:0.010348:0.010348:0.014581:0.006585
ADVANCED/UNRESECTABLE AND :@0.524242:0.669897:0.896304:0.669897:0.896304:0.650301:0.524242:0.650301:0.017404:0.016463:0.016463:0.017404:0.017404:0.018344:0.012230:0.016463:0.010819:0.015052:0.017404:0.013641:0.012230:0.012230:0.012230:0.018344:0.009878:0.017404:0.013641:0.010348:0.012230:0.006585:0.017404:0.017404:0.016463:0.006585
METASTATIC MELANOMA:@0.524242:0.689058:0.802701:0.689058:0.802701:0.669461:0.524242:0.669461:0.021167:0.012230:0.009878:0.017404:0.012230:0.009878:0.017404:0.009878:0.006585:0.018344:0.006585:0.021167:0.012230:0.010348:0.017404:0.017404:0.019756:0.021167:0.017404
IMMUNOTHERAPIES:@0.524242:0.707915:0.719232:0.707915:0.719232:0.690100:0.524242:0.690100:0.005987:0.019242:0.019242:0.013683:0.015822:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.005987:0.011118:0.011118
As early as the 1950s,  spontaneous  tu-:@0.524242:0.725289:0.915172:0.725289:0.915172:0.709533:0.524242:0.709533:0.014239:0.007466:0.011930:0.012508:0.013143:0.005792:0.003848:0.010314:0.011930:0.013143:0.007466:0.011930:0.006523:0.011738:0.012508:0.011930:0.010660:0.010660:0.010660:0.010660:0.007466:0.005330:0.005330:0.006614:0.007466:0.013123:0.012604:0.011738:0.006523:0.013143:0.011738:0.012508:0.012604:0.011699:0.007466:0.005330:0.006589:0.006523:0.011699:0.006388
mour  regressions have been shown with :@0.524242:0.741521:0.920483:0.741521:0.920483:0.725765:0.524242:0.725765:0.018049:0.012604:0.011699:0.005792:0.005330:0.004108:0.005713:0.012508:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.007466:0.009448:0.011738:0.013143:0.010660:0.012508:0.009448:0.013123:0.012508:0.012508:0.011738:0.009448:0.007466:0.011738:0.012604:0.015990:0.011738:0.009448:0.015990:0.003848:0.006523:0.011738:0.005330
immune-modulating agents, suggesting a :@0.524242:0.757753:0.920476:0.757753:0.920476:0.741997:0.524242:0.741997:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388:0.018049:0.012604:0.013181:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.006048:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.006048:0.007466:0.011699:0.012950:0.012950:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.006044:0.013143:0.005330
role for these agents in tumour therapeu-:@0.524242:0.773986:0.915151:0.773986:0.915151:0.758230:0.524242:0.758230:0.005713:0.012604:0.003848:0.012508:0.006896:0.006042:0.012604:0.005792:0.006891:0.006523:0.011738:0.012508:0.007466:0.012508:0.006895:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.006893:0.003848:0.011738:0.006908:0.006523:0.011699:0.018049:0.012604:0.011688:0.005792:0.006896:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011686:0.006388
tics. Interleukin-2 was the original therapy :@0.524242:0.790218:0.920506:0.790218:0.920506:0.774462:0.524242:0.774462:0.006523:0.003848:0.012450:0.007466:0.005330:0.007158:0.004349:0.011738:0.006523:0.012508:0.005792:0.003848:0.012508:0.011699:0.009660:0.003848:0.011738:0.006388:0.010660:0.007158:0.015990:0.013143:0.007466:0.007158:0.006523:0.011738:0.012508:0.007145:0.012604:0.005792:0.003848:0.012950:0.003848:0.011738:0.013143:0.003848:0.007158:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
utilised and  has  shown  modest  response :@0.524242:0.806450:0.920483:0.806450:0.920483:0.790694:0.524242:0.790694:0.011699:0.006523:0.003848:0.003848:0.003848:0.007466:0.012508:0.013181:0.008928:0.013143:0.011738:0.013181:0.005330:0.003587:0.011738:0.013143:0.007466:0.005330:0.003589:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330:0.003583:0.018049:0.012604:0.013181:0.012508:0.007466:0.006523:0.005330:0.003583:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
rates of around six to 16%.  Use of this agent :@0.524242:0.822682:0.920488:0.822653:0.920488:0.806897:0.524242:0.806926:0.005792:0.013143:0.006523:0.012508:0.007466:0.003737:0.012604:0.006042:0.003735:0.013143:0.005715:0.012604:0.011699:0.011738:0.013181:0.003739:0.007466:0.003848:0.009236:0.003752:0.006523:0.012604:0.003733:0.010660:0.010660:0.014913:0.005330:0.006208:0.003741:0.012604:0.007466:0.012508:0.003737:0.012604:0.006042:0.003735:0.006523:0.011738:0.003848:0.007466:0.003741:0.013143:0.012950:0.012508:0.011738:0.006523:-0.634280
9:@0.756327:0.817034:0.762542:0.817034:0.762542:0.807848:0.756327:0.807848:0.006215
has been  limited by treatment-related :@0.524246:0.838885:0.920495:0.838885:0.920495:0.823129:0.524246:0.823129:0.011738:0.013143:0.007466:0.014105:0.013123:0.012508:0.012508:0.011738:0.005330:0.008765:0.003848:0.003848:0.018049:0.003860:0.006523:0.012508:0.013181:0.014105:0.013123:0.010314:0.014105:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006388:0.005707:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
toxicities,  including  acute  constitutional :@0.524246:0.855117:0.920490:0.855117:0.920490:0.839361:0.524246:0.839361:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.005330:0.008188:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330:0.008188:0.013143:0.012450:0.011699:0.006523:0.012508:0.005330:0.008182:0.012450:0.012604:0.011738:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330
symptoms, chronic fatigue, myelosuppres-:@0.524246:0.871349:0.915161:0.871349:0.915161:0.855593:0.524246:0.855593:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.005330:0.004868:0.012450:0.011738:0.005709:0.012604:0.011738:0.003848:0.012450:0.004868:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.004857:0.018049:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.006388
sion, depression, thyroid dysfunction  and :@0.524246:0.887581:0.920488:0.887581:0.920488:0.871826:0.524246:0.871826:0.007466:0.003848:0.012604:0.011738:0.005330:0.008717:0.013181:0.012508:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.008717:0.006523:0.011738:0.010314:0.005709:0.012604:0.003848:0.013181:0.008717:0.013181:0.010314:0.007466:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003375:0.013143:0.011738:0.013181:0.005330
multi-organ  failure.  Its use is thus  limited :@0.524246:0.903814:0.920490:0.903814:0.920490:0.888058:0.524246:0.888058:0.018049:0.011699:0.003848:0.006523:0.003848:0.006388:0.012604:0.005805:0.012950:0.013143:0.011738:0.005330:0.004936:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.005330:0.005330:0.004934:0.004349:0.006523:0.007466:0.010275:0.011699:0.007466:0.012508:0.010275:0.003848:0.007466:0.010275:0.006523:0.011738:0.011699:0.007466:0.005330:0.004934:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330
by strict patient selection and preferential :@0.524246:0.920046:0.920459:0.920046:0.920459:0.904290:0.524246:0.904290:0.013123:0.010314:0.005734:0.007466:0.006523:0.005792:0.003848:0.012450:0.006523:0.005734:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005734:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005734:0.013143:0.011738:0.013181:0.005734:0.013123:0.005715:0.012508:0.006042:0.012508:0.005707:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.005330
use in experienced, high-volume centres. :@0.524246:0.936278:0.920509:0.936278:0.920509:0.920522:0.524246:0.920522:0.011699:0.007466:0.012508:0.007177:0.003848:0.011738:0.007177:0.012508:0.009236:0.013123:0.012508:0.005792:0.003848:0.012508:0.011738:0.012450:0.012508:0.013181:0.005330:0.007164:0.011738:0.003848:0.012950:0.011738:0.006388:0.010660:0.012604:0.003848:0.011699:0.018049:0.012508:0.007168:0.012450:0.012508:0.011738:0.006523:0.005703:0.012508:0.007466:0.005330:0.005330
Treatment Options for Inoperable  :@0.084848:0.111850:0.791216:0.111850:0.791216:0.076219:0.084848:0.076219:0.017960:0.013683:0.027367:0.028222:0.012828:0.040195:0.027367:0.025657:0.012828:0.011973:0.035919:0.028222:0.012828:0.010263:0.027367:0.025657:0.018815:0.011973:0.011973:0.027367:0.013683:0.011973:0.011973:0.025657:0.027367:0.028222:0.027367:0.013683:0.028222:0.028222:0.010263:0.027367:0.011930:0.011973
and Metastatic Malignant Melanoma:@0.084848:0.144187:0.853689:0.144187:0.853689:0.108557:0.084848:0.108557:0.028222:0.025657:0.028222:0.011973:0.038485:0.027367:0.012828:0.028222:0.018815:0.012828:0.028222:0.012828:0.010263:0.027367:0.011973:0.038485:0.028222:0.010263:0.010263:0.028222:0.025657:0.028222:0.025657:0.012828:0.011973:0.038485:0.027367:0.010263:0.028222:0.025657:0.027367:0.040195:0.028222